Takeda’s zasocitinib (TAK-279) has shown statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a phase III Latitude Atlas readout for moderate-to-severe plaque psoriasis. The topline result advances zasocitinib into a crowded psoriasis market where comparative performance and durability against established TYK2 approaches remain key. The trial readout also reinforces the importance of head-to-head framing in next-generation immunology drugs, particularly when competitors already hold established approvals. For payers and clinicians, the practical question becomes whether the advantage translates into meaningful response depth, speed, and safety/tolerability across relevant patient subgroups. With Sotyktu already approved, the result increases pressure on other TYK2 and mechanism-adjacent developers to refine positioning, endpoints, and patient selection as registrational and label-expansion decisions accumulate.